Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Met-CCL5 modifies monocyte subpopulations during liver fibrosis regression.

Stock MK, Hammerich L, do O NT, Berres ML, Alsamman M, Heinrichs D, Nellen A, Trautwein C, Tacke F, Wasmuth HE, Sahin H.

Int J Clin Exp Pathol. 2013;6(4):678-85. Epub 2013 Mar 15.

2.

Interference with oligomerization and glycosaminoglycan binding of the chemokine CCL5 improves experimental liver injury.

Nellen A, Heinrichs D, Berres ML, Sahin H, Schmitz P, Proudfoot AE, Trautwein C, Wasmuth HE.

PLoS One. 2012;7(5):e36614. doi: 10.1371/journal.pone.0036614. Epub 2012 May 4.

3.

Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice.

Berres ML, Koenen RR, Rueland A, Zaldivar MM, Heinrichs D, Sahin H, Schmitz P, Streetz KL, Berg T, Gassler N, Weiskirchen R, Proudfoot A, Weber C, Trautwein C, Wasmuth HE.

J Clin Invest. 2010 Nov;120(11):4129-40. doi: 10.1172/JCI41732. Epub 2010 Oct 18.

4.

The fractalkine receptor CX₃CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes.

Karlmark KR, Zimmermann HW, Roderburg C, Gassler N, Wasmuth HE, Luedde T, Trautwein C, Tacke F.

Hepatology. 2010 Nov;52(5):1769-82. doi: 10.1002/hep.23894.

PMID:
21038415
5.

RANTES antagonism: a promising approach to treat chronic liver diseases.

Affò S, Bataller R.

J Hepatol. 2011 Oct;55(4):936-8. doi: 10.1016/j.jhep.2011.04.023. Epub 2011 Jun 25.

6.

Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis.

Karlmark KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F, Weber C, Merad M, Luedde T, Trautwein C, Tacke F.

Hepatology. 2009 Jul;50(1):261-74. doi: 10.1002/hep.22950.

PMID:
19554540
7.

Lack of inducible nitric oxide synthase leads to increased hepatic apoptosis and decreased fibrosis in mice after chronic carbon tetrachloride administration.

Aram G, Potter JJ, Liu X, Torbenson MS, Mezey E.

Hepatology. 2008 Jun;47(6):2051-8. doi: 10.1002/hep.22278.

PMID:
18506890
8.

Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis.

Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C, Zernecke A, Tischendorf JJ, Luedde T, Weiskirchen R, Trautwein C, Tacke F.

PLoS One. 2010 Jun 10;5(6):e11049. doi: 10.1371/journal.pone.0011049.

9.

Human amniotic epithelial cell transplantation induces markers of alternative macrophage activation and reduces established hepatic fibrosis.

Manuelpillai U, Lourensz D, Vaghjiani V, Tchongue J, Lacey D, Tee JY, Murthi P, Chan J, Hodge A, Sievert W.

PLoS One. 2012;7(6):e38631. doi: 10.1371/journal.pone.0038631. Epub 2012 Jun 14.

10.

Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury.

Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, Gassler N, Huss S, Klussmann S, Eulberg D, Luedde T, Trautwein C, Tacke F.

Gut. 2012 Mar;61(3):416-26. doi: 10.1136/gutjnl-2011-300304. Epub 2011 Aug 3.

PMID:
21813474
11.

Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice.

Baeck C, Wei X, Bartneck M, Fech V, Heymann F, Gassler N, Hittatiya K, Eulberg D, Luedde T, Trautwein C, Tacke F.

Hepatology. 2014 Mar;59(3):1060-72. doi: 10.1002/hep.26783. Epub 2014 Jan 30.

PMID:
24481979
12.

Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection.

Yun JJ, Whiting D, Fischbein MP, Banerji A, Irie Y, Stein D, Fishbein MC, Proudfoot AE, Laks H, Berliner JA, Ardehali A.

Circulation. 2004 Feb 24;109(7):932-7. Epub 2004 Feb 2.

13.

Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans.

Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, Scholten D, Berres ML, Zimmermann H, Streetz KL, Tacke F, Hillebrandt S, Schmitz P, Keppeler H, Berg T, Dahl E, Gassler N, Friedman SL, Trautwein C.

Gastroenterology. 2009 Jul;137(1):309-19, 319.e1-3. doi: 10.1053/j.gastro.2009.03.053. Epub 2009 Apr 1.

14.

Monocytes and macrophages as cellular targets in liver fibrosis.

Heymann F, Trautwein C, Tacke F.

Inflamm Allergy Drug Targets. 2009 Sep;8(4):307-18. Review.

PMID:
19534673
15.

Peritoneal administration of Met-RANTES attenuates inflammatory and nociceptive responses in a murine neuropathic pain model.

Liou JT, Mao CC, Ching-Wah Sum D, Liu FC, Lai YS, Li JC, Day YJ.

J Pain. 2013 Jan;14(1):24-35. doi: 10.1016/j.jpain.2012.09.015. Epub 2012 Nov 23.

PMID:
23183003
16.

Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis.

Zimmermann HW, Tacke F.

Inflamm Allergy Drug Targets. 2011 Dec;10(6):509-36. Review.

PMID:
22150762
17.
18.

Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence.

Ohyama T, Sato K, Kishimoto K, Yamazaki Y, Horiguchi N, Ichikawa T, Kakizaki S, Takagi H, Izumi T, Mori M.

Br J Pharmacol. 2012 Feb;165(4b):1173-87. doi: 10.1111/j.1476-5381.2011.01599.x.

19.

Protease-activated receptor 2 promotes experimental liver fibrosis in mice and activates human hepatic stellate cells.

Knight V, Tchongue J, Lourensz D, Tipping P, Sievert W.

Hepatology. 2012 Mar;55(3):879-87. doi: 10.1002/hep.24784. Epub 2012 Jan 12.

PMID:
22095855
20.

The role of tumor necrosis factor-alpha in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride.

Simeonova PP, Gallucci RM, Hulderman T, Wilson R, Kommineni C, Rao M, Luster MI.

Toxicol Appl Pharmacol. 2001 Dec 1;177(2):112-20.

PMID:
11740910
Items per page

Supplemental Content

Write to the Help Desk